AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Weekly low-dose docetaxel maintains activity and is less myelosuppressive.
2003 OCT 2 - (NewsRx.com & NewsRx.net) -- Weekly low-dose docetaxel maintains activity and is less myelosuppressive in breast cancer.
"The purpose of this study was to evaluate the efficacy and toxicity of weekly docetaxel in metastatic breast cancer," researchers in Japan report.
"Fifty-seven patients were enrolled in this study of weekly docetaxel given at 25 mg/m[superscript]2/week as a 1-h infusion in an outpatient setting. Each cycle consisted of 3 weeks of therapy followed by 1-week treatment break, and the patients received a median of 24 infusions with a median cumulative dose of 600 mg/m[superscript]2," wrote K. Kuroi and colleagues, Showa University, Toyosu Hospital.
"Overall response rate was 30% [95% confidence interval (CI), 18%-42%], and 31% (18%-42%) of patients had stable disease for at least 6 months. With a median follow-up of 16 months, the median time to treatment failure was 11 months (6-14 M), and 3-year survival rate was 60%," the researchers wrote.
"There was no grade 4 toxicity, and myelosuppression, fatigue, nausea, and vomiting were mild, thus the regimen was generally well ...
- Weekly low-dose docetaxel maintains activity and is less myelosuppressive.
- Newspaper article from: Health & Medicine Week September 29, 2003 700+ words
...dose docetaxel maintains activity and is less myelosuppressive...Showa University, Toyosu Hospital. "Overall response...docetaxel at low dose maintains activity and is less myelosuppressive...Showa University, Toyosu Hospital, Department of...
- Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen...
- Press release article from: PR Newswire April 14, 2008 700+ words
Isis Will Host a Conference Call on Monday, April 14, at 8:30 a.m. E.T. at httpwww.isispharm.com CARLSBAD, Calif., April 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced additional results from its ongoing Phase 2 open-label extension (OLE) study of mipomersen in patients with
- Orphan drug designation granted for P113D.
- Newspaper article from: TB & Outbreaks Week December 10, 2002 700+ words
...patient clinical isolates of bacteria that are resistant to traditional antibiotics. The compound is stable and maintains activity in sputum of CF patients. A number of preclinical toxicology evaluations need to be completed before human trials...
- Boehringer Ingelheim reports resistance data on investigational drug Tipranavir...
- Press release article from: PR Newswire July 16, 2003 700+ words
...the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris suggest that tipranavir maintains activity against HIV that is resistant to other commercially available protease inhibitors (PIs). An unrelated large...
- Research reports on life sciences from University of Pennsylvania, Center for...
- Newspaper article from: Biotech Week January 28, 2009 700+ words
...nerve activity in rats.' According to a study from the United States, "Noradrenergic (NE) excitatory drive maintains activity of hypoglossal (XII) motoneurons during wakefulness. In predisposed persons, sleep-related decrements of...
- FREEDOM Group Announces Clients for TRACKER Unclaimed Property Software.
- Press release article from: Business Wire August 31, 1999 700+ words
...managing and filing unclaimed or abandoned property data. TRACKER also generates search letters to owners, maintains activity logs and creates reports in pre-approved formats for all states and jurisdictions. The FREEDOM Group, a unit...
- Demegen Receives Orphan Drug Designation for P113D For Treatment of Cystic...
- Press release article from: PR Newswire November 5, 2002 700+ words
...patient clinical isolates of bacteria that are resistant to traditional antibiotics. The compound is stable and maintains activity in sputum of CF patients. A number of preclinical toxicology evaluations need to be completed before human trials...
- MSX International's eBusiness Solution Delivers Results To Home Network Online...
- Press release article from: PR Newswire June 6, 2000 700+ words
...yard sign can direct drive-by traffic to the home listing on the Web site. An automatic notification feature maintains activity on the home by e-mailing subscribing buyers when any activity, such as a counter-offer, occurs. Home Network...